May. 15 at 5:26 PM
$CODX
Total revenue for the first quarter of 2026 was only
$146,000, compared to
$50,000 in the same period last year, indicating limited revenue growth.
The company reported a net loss of
$9.1 million for the quarter, an increase from a net loss of
$7.5 million in the same period last year.
Operating expenses increased to
$9.2 million, driven by higher research and development spending, impacting profitability.
Co-Diagnostics Inc (NASDAQ:CODX) expects to continue generating operating losses in the near term, indicating ongoing financial challenges.
